tbuckley/cabot-search huggingface dataset:
NCMP-01. RISK FACTORS ASSOCIATED WITH LATE HYPERGLYCEMIA IN BRAIN TUMOR PATIENTS WITH POSTOPERATIVE ADMINISTRATION OF DEXAMETHASONE
Authors: Seung Ho Yang
Journal: Neuro-Oncology (2019)

Abstract Dexamethasone is the corticosteroid most commonly used for the management of vasogenic edema in patients with brain tumors. The occurrence of hyperglycemia following corticosteroid administration is well known to physicians and health care givers. The purpose of the study is to investigate late onset of hyperglycemia and associated factors in patients with brain tumors. The inclusion criteria are as follows; 1) brain tumor patients underwent craniotomy; 2) steroid administered for at least 3 days longer perioperatively or postoperatively; 3) serum glucose levels examined for at least 3 months postoperatively The exclusion criteria are as follows; 1) steroid administered for less than 3 days; 2) patients diagnosed with type 1 diabetes, renal failure, hepatic failure or autoimmune diseases; 3) other medical illness treated with corticosteroid. A total of 101 patients were enrolled for the analysis. Fasting blood glucose of diabetes patients and non-diabetes patients was 160±93 mg/dl and 114±43 mg/dl, respectively. There was no difference of type of brain tumors, body mass index, hypertension, smoking history, hyperlipidemia, GOT, GPT, ESR, CRP, and Cr between diabetes patients and non-diabetes patients. The peak of Fasting blood glucose was noted on day 1 postoperatively in non-diabetes patients. Two peak of Fasting glucose levels were found on day 1 and 6 postoperatively in diabetes patients. Late hyperglycemia was determined as in patients with fasting blood glucose of &gt;125 mg/dl during 3~6 months postoperatively. Fifteen patients out of 86 non-diabetes patients developed late hyperglycemia. There were significant differences of duration and total dose of dexamethasone administration between late hyperglycemia patients and non-late hyperglycemia patients. Steroid-induced hyperglycemia can develop late postoperatively even in non-diabetic patients with brain tumor treated with dexamethasone. Fasting blood glucose during the first week postoperatively can predict late hyperglycemia. Duration and total dosage of dexamethasone administered are associated with late hyperglycemia.
Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis
Authors: Youngmin Kwon, Timothy J Bell, Caitlyn Solem, Joseph C Cappelleri, Courtney Johnson, Helen Bhattacharyya, Caroline J. Hoang, Jorge E. Cortes
Journal: Blood (2019)
A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome
Authors: Angela Dispenzieri, Michelle Mauermann, Betsy Laplant, Martha Q. Lacy, Ronald S. Go, Prashant Kapoor, Yi L. Hwa, Amie Fonder, Miriam A. Hobbs, Francis K. Buadi, Suzanne R. Hayman, Nelson Leung, John A. Lust, David Dingli, Wilson I Gonsalves, Taxiarchis Kourelis, Rahma M Warsame, S.Vincent Rajkumar, Shaji K. Kumar, Morie A Gertz
Journal: Blood (2019)
Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls
Authors: Valerio De Stefano, Arianna Ghirardi, Arianna Masciulli, Alessandra Carobbio, Francesca Palandri, Nicola Vianelli, Elena Rossi, Silvia Betti, Ambra Di Veroli, Alessandra Iurlo, Daniele Cattaneo, Guido Finazzi, Massimiliano Bonifacio, Luigi Scaffidi, Andrea Patriarca, Elisa Rumi, Ilaria Carola Casetti, Clemency Stephenson, Paola Guglielmelli, Elena Maria Elli, Miroslava Palova, Davide Rapezzi, Daniel Erez, Montse Gomez, Kai Wille, Manuel Pérez-Encinas, Francesca Lunghi, Anna Angona, Maria Laura Fox, Eloise Beggiato, Giulia Benevolo, Giuseppe Carli, Rossella Rosaria Cacciola, Mary Frances McMullin, Alessia Tieghi, Valle Recasens, Monia Marchetti, Martin Griesshammer, Alberto Alvarez-Larrán, Alessandro M. Vannucchi, Alessandro Rambaldi, Tiziano Barbui
Journal: Blood (2019)
TMOD-17. A SWINE MODEL OF GLIOBLASTOMA INDUCED BY SOMATIC GENE MODIFICATION
Authors: Barbara Tschida, Dylan Duerre, Mandy Taisto, Staci Solin, Adrienne Watson
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common and malignant primary brain tumor. New, effective treatments for GBM are needed since the standard of care universally fails to cure patients. A major hurdle for GBM therapeutic development is the lack of relevant large animal models with high translational value for preclinical studies. To overcome this, we are developing a model of GBM in outbred, immune-proficient swine which have comparable brain size and anatomy to humans. GBM tumors will be driven by somatic alterations to major signaling pathways frequently altered in human GBM and will express a secreted reporter for tumor growth detectable in the peripheral blood. These alterations and reporter expression cassettes will be induced by delivering transposons and CRISPR/Cas9 gene-editing tools to the subventricular brain cells of live swine by stereotactic injections. We have developed and deployed these gene-editing tools, demonstrating their efficacy in swine cells. We have identified stereotactic coordinates to reproducibly target the lateral ventricles of neonatal swine brains and have demonstrated successful plasmid delivery to cells at these coordinates. Stable, persistent transposon integration and clonal expansion of modified cells has been confirmed by sequencing transposon-genomic DNA junctions in brain tissue six-months post-injection. To induce GBM-like tumors, we have introduced gene delivery and gene editing reagents to alter six major human GBM-associated signaling pathways in a cohort of swine. Resulting tumors will be examined molecularly to detect the pathway-associated transposons and CRISPR/Cas9-induced mutations in tumor tissue and determine the resemblance to human GBM. This somatic cell gene-modification platform will be adaptable, allowing on-demand inclusion of preclinical study-relevant alterations in GBM tumors, and will allow the rapid development tumors histologically and genetically similar to human GBM, which will be valuable for use in pre-clinical therapeutic studies, imaging studies using human clinical grade equipment, and surgical technique development.
Human–machine partnership with artificial intelligence for chest radiograph diagnosis
Authors: Bhavik N. Patel, Louis Rosenberg, Gregg Willcox, David Baltaxe, Mimi Lyons, Jeremy Irvin, Pranav Rajpurkar, Timothy Amrhein, Rajan Gupta, Safwan Halabi, Curtis Langlotz, Edward Lo, Joseph Mammarappallil, A. J. Mariano, Geoffrey Riley, Jayne Seekins, Luyao Shen, Evan Zucker, Matthew P. Lungren
Journal: npj Digital Medicine (2019)

Human-in-the-loop (HITL) AI may enable an ideal symbiosis of human experts and AI models, harnessing the advantages of both while at the same time overcoming their respective limitations. The purpose of this study was to investigate a novel collective intelligence technology designed to amplify the diagnostic accuracy of networked human groups by forming real-time systems modeled on biological swarms. Using small groups of radiologists, the swarm-based technology was applied to the diagnosis of pneumonia on chest radiographs and compared against human experts alone, as well as two state-of-the-art deep learning AI models. Our work demonstrates that both the swarm-based technology and deep-learning technology achieved superior diagnostic accuracy than the human experts alone. Our work further demonstrates that when used in combination, the swarm-based technology and deep-learning technology outperformed either method alone. The superior diagnostic accuracy of the combined HITL AI solution compared to radiologists and AI alone has broad implications for the surging clinical AI deployment and implementation strategies in future practice.
IMMU-20. ADVANCED AGING INCREASES IMMUNOSUPPRESSIVE IDO1 LEVELS THAT ARE UNINHIBITED BY IDO1 ENZYME INHIBITOR TREATMENT IN MODELS OF GLIOBLASTOMA
Authors: Erik Ladomersky, Lijie Zhai, Kristen Lauing, Jun Qian, Sebastian Otto-Meyer, Rohan Savoor, Derek Wainwright
Journal: Neuro-Oncology (2019)

Abstract Immunotherapy has failed to improve the overall survival (OS) of adults with GBM in all phase III clinical trials to-date. Somewhat less appreciated is that, de novo GBM is a disease associated with a median age of diagnosis at 64 years old. Because of the strong association between advanced aging and human subjects presenting with GBM, we further investigated our previously described observation of a higher mortality rate in elderly C57BL/6 wild-type (WT) mice with intracranial GL261 as compared to young counterparts after treatment with radiotherapy (RT) and anti-PD-1 (PD1)/IDO1 enzyme inhibitor (IDO1i) (Ladomersky et al., 2018; Clinical Cancer Research). Since immunosuppressive IDO1 expression significantly increases in both the mouse and human brain during advanced aging (Ladomersky et al., 2019; Frontiers in Pharm.), we decided to study how IDO1 and aging interact during immunotherapy of GBM. We found that the pretreatment effects of an IDO1 enzyme inhibitor improve OS in young but not elderly WT mice with intracranial GL261 (n=12–15/group; p&lt; 0.05). Strikingly, in the setting of advanced aging, IDO1-/- mice with GBM show improved OS as compared with WT mice (p&lt; 0.01) independent of treatment with an IDO1 enzyme inhibitor. Similarly stunning, 74–80 week old IDO1-/- mice with GBM treated at 14 days post-ic. with RT and PD1/IDO1i survive significantly longer as compared to elderly WT mice administered the same treatment (n=20–22/group; p&lt; 0.05). These results collectively suggest that, the therapeutic effects of IDO1 enzyme inhibition is less effective in the setting of old age, and provides rationale for the development of new approaches that inhibit IDO1-mediated immunosuppression independent of its association with enzyme activity for eventually improving immunotherapeutic efficacy in human subjects with malignant glioma.
Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML
Authors: Matthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, Emmanuel Raffoux, Xavier Thomas, Jean-Pierre Marolleau, Thorsten Braun, Lionel Ades, Sylvain Chantepie, Emilie Lemasle, Celine Berthon, Jean Valère Malfuson, Cecile Pautas, Juliette Lambert, Nicolas Boissel, Karine Celli-Lebras, Denis Caillot, Pascal Turlure, Norbert Vey, Arnaud Pigneux, Christian Recher, Christine Terré, Claude Gardin, Raphael Itzykson, Claude Preudhomme, Herve Dombret, Stephane De Botton
Journal: Blood (2019)
Hematological Profile in the Saudi Population: Reference Intervals By Gender, Age and Regions
Authors: Ahmed Alaskar, Hina Rehan, May Anne Mendoza, Aljowhara Alsahan, Anita Immanuel, Ayman Alhejazi, Khadega Abuelgasim, Hind Salama, Moussab Damlaj, Giamal Gmati, Mohsen Alzahrani, Mushtaq Rather, Bader Alahmari, Areej Al Mugairi, Anwar Ahmed
Journal: Blood (2019)
An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide /Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
Authors: Maneesha Mehra, Sarah Cote, Tobias Kampfenkel, Sandhya Nair
Journal: Blood (2019)
High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia
Authors: Tom Erkers, Brinton Seashore-Ludlow, Nona Struyf, Francesco Marabita, Tojo James, Disha Malani, Mattias Vesterlund, Matthias Stalhl, Yudi Pawitan, Sören Lehmann, Päivi Östling, Janne Lehtiö, Olli Kallioniemi
Journal: Blood (2019)
Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors
Authors: Jennifer Berano Teh, Farah Abdulla, Kelly Peng, Liezl Atencio, Alicia Gonzales, Meagan Echevarria, Alex Iukuridze, Alan Geller, Heeyoung Kim, Lennie Wong, Stephen J Forman, Ryotaro Nakamura, Badri Modi, Saro H. Armenian
Journal: Blood (2019)
Magneto‐Fluorescent Perovskite Nanocomposites for Directed Cell Motion and Imaging
Authors: Max J. H. Tan, Divyapoorani Ravichandran, Hui Li Ang, Evon Woan Yuann Ong, Cheryldine Qiu Xuan Lim, Gabriel M. Q. Kam, Alan P. Kumar, Zhi‐Kuang Tan
Journal: Advanced Healthcare Materials (2019)

Abstract The ability for a magnetic field to penetrate biological tissues without attenuation has led to significant interest in the use of magnetic nanoparticles for biomedical applications. In particular, active research is ongoing in the areas of magnetically guided drug delivery and magnetic hyperthermia treatment. However, the difficulties in tracing these optically nonactive magnetic nanoparticles hinder their usage in medical research or treatment. Here, a new perovskite‐based magneto‐fluorescent nanocomposite that allows the in situ, real‐time optical visualization of magnetically induced cellular movements is reported. A swelling–deswelling technique is employed to capture a cesium lead halide perovskite and magnetite nanoparticles within a biocompatible polyvinylpyrrolidone matrix, to produce a water‐dispersible composite that possesses a combination of strong magnetic response and intense fluorescence. The wavelength‐tunability of perovskite nanocrystals is taken advantage of to demonstrate simultaneous multicolor fluorescent tagging of cancer stem cells. The magneto‐directed motion of the cancer stem cells through a microfluidic channel is also imaged as a proof‐of‐concept toward an optically traceable magnetic manipulation of biological systems. These dual‐functional nanocomposites could find promising applications in advanced biotechnologies, such as in optogenetics, cellular separation, and drug delivery studies.
Low Dose of Eltrombopag with Long-Term Response in Children with Severe Aplastic Anemia, Less Morbi-Mortality Better Quality of Life
Authors: Norma C Lopez-Santiago, Rogelio a Paredes Aguilera, Angelica Cecilia Monsivais Orozco, Maria De Lourdes Gonzalez Pedroza, Gabriela Tavera Rodriguez, Mara Toscano
Journal: Blood (2019)
Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)
Authors: Douglas W. Blayney, Lan Huang, Ramon Mohanlal
Journal: Blood (2019)
Gene expression profiling of cervical cancer and cell line models
Authors: Mark W. Carlson, Vishwanath Iyer, Edward Marcotte
Journal: Cancer Research (2006)

869  Introduction: The main objective of this research was to determine how well cervical cancer cell lines model cervical cancer by using gene expression profiling. Many studies choose one or two cervical cancer cell lines without regard to how well they actually represent tissue. Therefore, the outcome of this research was to characterize nine commonly used cell lines in terms of normal cervical tissue and invasive cervical cancer based on a collection of samples. In addition, several cell lines were cultured in different types of media to investigate media changes and model performance. Finally, several cell lines were also cultured in organotypic environments where they are more phenotypically similar to actual cervical tissue. It was our hypothesis that it is possible to increase the accuracy of cell lines as models of cancer by 1) simply selecting different media, 2) culturing cell lines in an organotypic environment, and 3) selecting primary cell lines obtained from an in vivo source. Methods: Individual cell lines were cultured three times independently to account for biological variation. Biopsies were obtained through various tissue banks. In all samples, total RNA was isolated, mRNA was amplified, and cDNA was generated and hybridized to cDNA microarrays containing 45,000 unique sequences. In each experiment, a universal human reference was used to enable expression profile comparisons among all experiments. Results: In order to identify which cell lines and conditions best model tissue, we compared the gene expression of each cell line and condition to the gene expression of a set of cervical cancers. Better cell line models have more expression overlap with the cancer set and thus have a higher correlation coefficient. Our results indicate that many things can be done to improve the performance of cell lines as models of tissue. Adding more nutrients to the media SiHa cells were cultured in vastly improved their performance in modeling invasive cervical cancer. Culturing cell lines in an organotypic environment also improves their performance as a model. Primary cells obtained from patients were the best models of cervical cancer. However, as obtaining and culturing primary cells is difficult, the next best model would be to use the cell line C4-I. However, despite the fact that some models are better than others, in general expression correlation between cell lines and tissues is low, indicating cell lines are poor models of tissue. Conclusions: In conclusion, selecting appropriate cell lines as models of cervical cancer should not be an arbitrary process. When researching a particular gene, it is not only necessary that the cell line chosen expresses the gene of interest, but we can also move beyond a single gene emphasis and chose a model that more closely represents the tissue of interest. This can be optimized by examining media effects and culturing in an organotypic environment.
QOLP-07. A PILOT STUDY TO ASSESS THE INTEGRATION OF A UNIQUE PROQOL TOOL AND EARLY PALLIATIVE CARE INTERVENTION IN THE CARE OF HIGH GRADE GLIOMA PATIENTS AND THEIR CAREGIVERS
Authors: Akanksha Sharma, Eric Wolfe, Celina Barrera, Samantha Williamson, Hannah Farfour, Maciej Mrugala, Mark Edwin, Jeff Sloan, Alyx Porter
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Early involvement of palliative care (PC) in patients with metastatic cancer has been associated with improved quality of life (QOL). Patients with high grade glioma (pwHGG) and their caregivers have unique needs such that similar results are anticipated in this population but cannot be extrapolated. Recognizing that pwHGG often require a caregiver early in the course of disease, this patient population also experiences significant personal and caregiver distress that has been given limited attention and resources. AIM: To assess the feasibility of implementation of a novel patient reported outcomes (PRO) quality of life (QOL) tool administered by smart device in routine office visit (OV) and early integration of palliative care (PC) for pwHGG and their caregivers to improve QOL for both. DESIGN: Prospective, single-center cluster-randomized pilot conducted for 6 months during completion of adjuvant therapy for newly diagnosed high grade glioma. After informed consent was obtained, 15 pwHGG and their caregivers were randomized to: routine OV with basic QOL survey; OV with PROQOL; or PC consultation, in addition to OV with PROQOL. RESULTS Two elderly patients with declining performance status transitioned to hospice after initial visit, and one moved out of state prior to adjuvant visits. Thus far 5/15 patients/caregivers have successfully completed the pilot with the 6 remaining participants due to complete in November 2019. DISCUSSION The PROQOL appears to be easily integrated into OV without significant patient, caregiver, or provider burden. Providers confirmed utility in prioritizing symptoms and concerns. Thus far, it appears that patients (and caregivers) appeared to benefit from the PROQOL and PC support as evidenced by longitudinal improvement in QOL scores over the control group. CONCLUSIONS A unique PROQOL tool and early PC can be easily integrated into practice, and may improve the QOL of pwHGG and their caregivers.
Reinforcement Learning to Optimize the Treatment of Multiple Myeloma
Authors: Kenneth H. Shain, Daniel Hart, Ariosto Siqueira Silva, Raghunandanreddy Alugubelli, Gabriel De Avila, Praneeth Reddy Sudalagunta, Alexandre Tungesvik, Amit Kulkarni, Carmelo Blancuicett, Hongyue Dai, Taiga Nishihori, Jason B. Brayer, Brandon Blue, Melissa Alsina, Rachid Baz, William S. Dalton
Journal: Blood (2019)
Review: No high-certainty evidence exists that nutritional supplements or diets affect cardiovascular outcomes
Authors: Lawrence J. Cheskin, Margaret Slavin
Journal: Annals of Internal Medicine (2019)

Source Citation Khan SU, Khan MU, Riaz H, et al. Effects of nutritional supplements and dietary interventions on cardiovascular outcomes: an umbrella review and evidence map. Ann Intern Med. 2019;171:190-8. 31284304
A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
Authors: C. Michel Zwaan, Edward Anders Kolb, Derek E. Mires, Michele Vigliotti, Jingdong Xie, Pamela Downs, Arthur P DeCillis, Cara A Rabik, Todd M Cooper
Journal: Blood (2019)
Parallel Signaling through IRE1α and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival
Authors: Paul C. Moore, Jenny Y. Qi, Maike Thamsen, Rajarshi Ghosh, Justin Peng, Micah J. Gliedt, Rosa Meza-Acevedo, Rachel E. Warren, Annie Hiniker, Grace E. Kim, Dustin J. Maly, Bradley J. Backes, Feroz R. Papa, Scott A. Oakes
Journal: Cancer Research (2019)

Abstract Master regulators of the unfolded protein response (UPR), IRE1α and PERK, promote adaptation or apoptosis depending on the level of endoplasmic reticulum (ER) stress. Although the UPR is activated in many cancers, its effects on tumor growth remain unclear. Derived from endocrine cells, pancreatic neuroendocrine tumors (PanNET) universally hypersecrete one or more peptide hormones, likely sensitizing these cells to high ER protein-folding stress. To assess whether targeting the UPR is a viable therapeutic strategy, we analyzed human PanNET samples and found evidence of elevated ER stress and UPR activation. Genetic and pharmacologic modulation of IRE1α and PERK in cultured cells, xenograft, and spontaneous genetic (RIP-Tag2) mouse models of PanNETs revealed that UPR signaling was optimized for adaptation and that inhibiting either IRE1α or PERK led to hyperactivation and apoptotic signaling through the reciprocal arm, thereby halting tumor growth and survival. These results provide a strong rationale for therapeutically targeting the UPR in PanNETs and other cancers with elevated ER stress. Significance: The UPR is upregulated in pancreatic neuroendocrine tumors and its inhibition significantly reduces tumor growth in preclinical models, providing strong rationale for targeting the UPR in these cancers.
Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort
Authors: Tarsheen Sethi, Alexandra E. Kovach, Emily F Mason, Heidi Chen, Tamara Moyo, Olalekan O. Oluwole, David Morgan, Nishitha Reddy
Journal: Blood (2019)